What's better, berberine or nattokinase?

Berberine and nattokinase are not competitors — they are not even playing the same sport.

One is a plant alkaloid tested across 49 randomised trials for blood sugar and cholesterol [5]. The other is a fermented-soy enzyme tested in six trials for blood pressure and clot breakdown [2].

Asking which is "better" is like asking whether a wrench beats a screwdriver. This guide compares what each one actually does, what the evidence supports, and how to tell which — if either — fits your goal.

Table of Contents

1. Berberine and Nattokinase Solve Different Problems
2. What the Berberine Research Actually Shows
3. What the Nattokinase Research Actually Shows
4. Absorption and Dose: Two Very Different Design Problems
5. Safety, Side Effects and Drug Interactions
6. How to Choose Between Berberine and Nattokinase
7. Getting the Studied Dose Intact: Why Enzyme Delivery Matters
8. Frequently Asked Questions
9. Conclusion
10. Research References

1. Berberine and Nattokinase Solve Different Problems

Berberine is an isoquinoline alkaloid found in goldenseal, barberry and Oregon grape. Researchers believe it works largely by activating AMP-activated protein kinase, and the NCCIH notes it also appears to change how the liver processes cholesterol and triglycerides [10] while influencing gut bacteria. Every one of those targets sits on the metabolic side of the body.

Nattokinase does something entirely different. It is a serine protease produced when Bacillus subtilis ferments soybeans into natto, and its documented activity is fibrinolytic and antithrombotic [8] — it breaks down fibrin, the protein mesh that holds a clot together. It has no meaningful role in glucose control.

The clearest proof that these are separate jobs comes from the nattokinase trial data itself. In the pooled analysis, nattokinase produced a small but statistically significant increase in blood glucose compared with placebo [2] — the opposite direction to berberine's entire evidence base.

2. What the Berberine Research Actually Shows

Berberine's strongest signal is glycemic. A 2022 meta-analysis of 37 studies and 3,048 patients with type 2 diabetes found reductions in fasting plasma glucose of 0.82 mmol/L, HbA1c of 0.63% and 2-hour post-meal glucose of 1.16 mmol/L [4]. Notably, it did not raise hypoglycemia risk, with a relative risk of 0.48 [4].

The lipid data is comparable in size. A dose-response meta-analysis of 49 randomised trials reported drops of 23.70 mg/dl in triglycerides, 20.64 mg/dl in total cholesterol and 9.63 mg/dl in LDL [5], with the optimal dose landing around 1 g per day.

Three caveats deserve equal weight:

• 38 of the 49 trials in that analysis were rated high risk of bias; only 5 were rated low [5]. Every pooled outcome in that paper carries a GRADE certainty rating of low or very low.
• Diastolic blood pressure did not reach significance (a 2.74 mmHg change, p = 0.063) [5].
• The NCCIH states that evidence for berberine as a weight-loss aid is not conclusive [10], despite the "nature's Ozempic" framing circulating online.

The honest summary is that berberine has the larger evidence base and the weaker one. More trials, more outcomes, lower methodological quality.

3. What the Nattokinase Research Actually Shows

The foundational human trial gave 86 adults with systolic pressure between 130 and 159 mmHg either 2,000 fibrinolytic units of nattokinase or placebo for eight weeks. Among the 73 who completed it, systolic pressure fell 5.55 mmHg further than control and diastolic fell 2.84 mmHg [1]. Renin activity also dropped by 1.17 ng/mL/h [1].

A later meta-analysis pooling six trials and 546 participants found a smaller but consistent effect: 3.45 mmHg systolic and 2.32 mmHg diastolic [2], with no notable adverse events reported in any group. That review rated the overall methodological quality of its included studies as high — a smaller evidence base than berberine's, but a cleaner one.

Then there is the result most articles skip. The Nattokinase Atherothrombotic Prevention Study followed 265 adults with a median age of 65.3 for a median of three years on the same 2,000 FU dose. It found no significant change in carotid artery thickness, arterial stiffness, blood pressure or any laboratory measure [3]. That is a genuine limitation, and it suggests nattokinase may matter more for people with elevated readings than for healthy adults at low cardiovascular risk.

4. Absorption and Dose: Two Very Different Design Problems

Berberine's central engineering problem is that almost none of it gets in. Oral bioavailability sits under 1% [6], driven by poor intestinal absorption and heavy first-pass removal. Manufacturers compensate with volume — across the 49 pooled trials, daily doses ranged from under half a gram to more than six grams [5].

That volume has a cost. The same paper cites a 13-week study in which gastrointestinal adverse events reached 34.5% of participants [6], concentrated in the first four weeks.

Nattokinase faces the opposite problem. It is an enzyme, not a small molecule, so the challenge is not absorption volume but survival — stomach acid can denature it before it reaches the small intestine. That is why delivery format matters more here than dose escalation does. The BioAbsorb Nattokinase Enzyme delivers 100 mg at 2,000 FU in a single daily capsule — the same activity level used in both the blood pressure trial [1] and the three-year atherosclerosis study [3].

5. Safety, Side Effects and Drug Interactions

Berberine's main risk is pharmacokinetic. In an NCCIH-funded study, healthy adults given goldenseal extract alongside metformin saw metformin levels fall by roughly 25% [11] — a meaningful shift for anyone relying on that medication. NCCIH also flags that berberine is likely unsafe for infants and may be unsafe during pregnancy or breastfeeding [10], and that some commercial goldenseal products were found to contain undisclosed ingredients [11].

Nattokinase's main risk is bleeding-related. Memorial Sloan Kettering notes it may increase the risk of intracerebral hemorrhage when combined with aspirin [9], and documents a case in which a patient required repeat valve replacement after self-substituting nattokinase for warfarin.

Against that, a formal toxicology assessment covering several GLP-compliant rodent and human studies found no indication of adverse effects [7] in trials of anticoagulant and antihypertensive activity — though that assessment was commissioned by a nattokinase manufacturer, which is worth knowing when weighing it against the case reports above. The practical rule for both compounds is the same: if you take prescription medication, this is a conversation with your doctor before it is a purchase decision.

6. How to Choose Between Berberine and Nattokinase

Start from the biomarker you are actually trying to move, not from which supplement is more talked about. The two compounds barely overlap, so the decision is usually straightforward once the goal is named.

• Elevated HbA1c, fasting glucose or LDL: berberine has the relevant data — 37 trials on glycemia alone [4].
• Elevated blood pressure or concern about fibrin and circulation: nattokinase has the relevant data, with 2,000 FU as the studied dose [1].
• Healthy, low-risk and simply hoping to prevent something: the three-year NAPS trial found no measurable benefit in exactly that population [3].
• On anticoagulants, antiplatelets, metformin or a CYP3A4-metabolised statin: neither, without medical supervision.

Combining them is not automatically unreasonable, since the mechanisms do not compete. But no trial has tested the combination, so anyone considering it is running an experiment of one and should say so to their physician rather than assume additive benefit.

7. Getting the Studied Dose Intact: Why Enzyme Delivery Matters

With an enzyme, the number on the label only means something if the enzyme reaches the small intestine still folded and active. Standard enteric coatings solve this, but many rely on phthalates and plasticizers to do it.

BioAbsorb built its Nattokinase Enzyme around DRcaps delayed-release veggie capsules instead — protecting the enzyme from stomach acid without those additives. Each capsule delivers 100 mg of non-GMO natto extract at 2,000 FU, matching the activity level used in the published human trials, taken once daily on an empty stomach.

Two formulation decisions are worth naming. The product is deliberately free of vitamin K2, which matters because natto is naturally rich in K2 and high K2 intake can interfere with warfarin monitoring — removing it makes longer-term dosing cleaner for readers already supplementing K2 elsewhere. It is also free of gluten, nuts, eggs, dairy, fish, shellfish and all animal products, making it fully vegetarian.

Manufacturing happens in a GMP-certified Canadian facility, with every batch third-party tested for nattokinase activity, heavy metals, gluten and microbial contaminants. The 180-capsule size runs $49.87, or roughly $0.28 per day — a six-month supply at the single-capsule protocol. None of this makes nattokinase work better than the trials show it works; it makes the trial dose reproducible, which is a lower and more honest claim.

Frequently Asked Questions

Can I take berberine and nattokinase together?

Mechanistically there is no known conflict — one acts on metabolic pathways, the other on fibrin — so the combination is not inherently contradictory. However, no clinical trial has tested them together, and both carry interaction risks with common medications, so this should be cleared with a physician first.

Is berberine really "nature's Ozempic"?

No. Berberine's primary mechanism is AMPK activation, which is pharmacologically unrelated to how GLP-1 receptor agonists work. The NCCIH states that evidence for berberine as a weight-loss aid is not conclusive [10].

Which one lowers blood pressure more?

Berberine's 49-trial meta-analysis reported a 5.46 mmHg systolic reduction [5], and nattokinase's foundational trial reported 5.55 mmHg [1]. The figures look similar, but they come from different populations and trial designs, so treating them as directly comparable would overstate what the data can support.

Does nattokinase help with blood sugar?

The evidence points the other way. In the pooled six-trial analysis, nattokinase produced a slight increase [2] in blood glucose relative to placebo. It should not be chosen as a glycemic supplement.

Why does berberine cause stomach upset?

Because so little is absorbed — under 1% of an oral dose [6] — most of it stays in the gut, where it interacts with gut bacteria. Doses are raised to compensate, and the same paper cites a 13-week study in which gastrointestinal side effects reached 34.5% [6].

Who should avoid nattokinase entirely?

Anyone taking anticoagulant or antiplatelet medication, anyone with a bleeding disorder, and anyone scheduled for surgery. Memorial Sloan Kettering documents both hemorrhage risk alongside aspirin and severe allergic reactions [9] in people allergic to natto.

Conclusion

"Which is better" is the wrong question — berberine belongs to metabolic health and nattokinase to fibrinolysis and blood pressure, and the six-trial pooled data showing a 3.45 mmHg systolic reduction [2] tells you nothing about your HbA1c. Name your biomarker first, then choose. If that biomarker is blood pressure or circulation, the BioAbsorb Nattokinase Enzyme delivers the 2,000 FU dose the research was built on.

For a fuller grounding in how this enzyme works, see our complete guide to nattokinase, along with how much nattokinase to take and when, and the drug interactions worth knowing about.

Research References

1. Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertension Research, Vol. 31 (2008). Found that 2,000 FU of nattokinase daily for eight weeks reduced systolic pressure by 5.55 mmHg and diastolic by 2.84 mmHg versus control in 73 completing participants.
2. Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Reviews in Cardiovascular Medicine, Vol. 24 (2023). Pooled six trials and 546 participants, finding blood pressure reductions alongside a slight increase in blood glucose.
3. Nattokinase atherothrombotic prevention study: A randomized controlled trial. Clinical Hemorheology and Microcirculation, Vol. 78 (2021). Found no effect of nattokinase on carotid artery thickness, arterial stiffness or blood pressure over a median three years in 265 low-risk adults.
4. Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis. Frontiers in Pharmacology, Vol. 13 (2022). Across 37 studies and 3,048 patients, berberine reduced HbA1c by 0.63% and fasting plasma glucose by 0.82 mmol/L without raising hypoglycemia risk.
5. The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis. Frontiers in Nutrition, Vol. 9 (2022). Analysed 49 randomised trials, reporting lipid, glycemic and systolic blood pressure improvements, with 38 studies rated high risk of bias.
6. Absorption Kinetics of Berberine and Dihydroberberine and Their Impact on Glycemia: A Randomized, Controlled, Crossover Pilot Trial. Nutrients, Vol. 14 (2022). Documented berberine's sub-1% oral bioavailability and cited gastrointestinal adverse events of 34.5% in a 13-week trial.
7. Toxicological assessment of nattokinase derived from Bacillus subtilis var. natto. Food and Chemical Toxicology, Vol. 88 (2016). GLP-compliant rodent and human studies found no indication of adverse effects from nattokinase supplementation. Assessment prepared for a commercial nattokinase manufacturer.
8. Nattokinase as an adjuvant therapeutic strategy for non-communicable diseases. Expert Review of Cardiovascular Therapy, Vol. 22 (2024). Narrative review describing nattokinase's fibrinolytic, antithrombotic, anti-inflammatory and antioxidant mechanisms.
9. Nattokinase — Integrative Medicine Herb Database. Memorial Sloan Kettering Cancer Center. Documents bleeding risk alongside aspirin, a valve thrombosis case following warfarin substitution, and allergic reactions in natto-sensitive patients.
10. Berberine and Weight Loss: What You Need To Know. National Institutes of Health — National Center for Complementary and Integrative Health. States that weight-loss evidence for berberine is not conclusive and that it is likely unsafe for infants and possibly unsafe in pregnancy.
11. Goldenseal: Usefulness and Safety. National Institutes of Health — National Center for Complementary and Integrative Health. Reports that goldenseal extract reduced metformin blood levels by roughly 25% in healthy adults.

About the Author

David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

FDA/Health Canada Statement: These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.